MedTrace Logo

177Lu-labeled NY108 SPECT Imaging in Patients

NCT05815394 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled NY108 (177Lu-NY108) SPECT Imaging in patients.

Conditions

Interventions

DRUG

177Lu-labeled NY108

Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Principal Investigators

  • Chunjing Yu · Affiliated Hospital of Jiangnan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-03
Primary Completion
2024-03-03
Completion
2024-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815394 on ClinicalTrials.gov